Gastric cancer is the second leading cause of cancer-related deaths worldwide. In advanced and metastatic gastric cancer, the conventional chemotherapy with limited efficacy shows an overall survival period of about 10 months. Patient specific and effective treatments known as personalized cancer therapy is of significant importance. Advances in high-throughput technologies such as microarray and next generation sequencing for genes, protein expression profiles and oncogenic signaling pathways have reinforced the discovery of treatment targets and personalized treatments. However, there are numerous challenges from cancer target discoveries to practical clinical benefits. Although there is a flood of biomarkers and target agents, only a minority of patients are tested and treated accordingly. Numerous molecular target agents have been under investigation for gastric cancer. Currently, targets for gastric cancer include the epidermal growth factor receptor family, mesenchymal-epithelial transition factor axis, and the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathways. Deeper insights of molecular characteristics for gastric cancer has enabled the molecular classification of gastric cancer, the diagnosis of gastric cancer, the prediction of prognosis, the recognition of gastric cancer driver genes, and the discovery of potential therapeutic targets. Not only have we deeper insights for the molecular diversity of gastric cancer, but we have also prospected both affirmative potentials and hurdles to molecular diagnostics. New paradigm of transdisciplinary team science, which is composed of innovative explorations and clinical investigations of oncologists, geneticists, pathologists, biologists, and bio-informaticians, is mandatory to recognize personalized target therapy.
Introduction
The personalized cancer therapy target aberrations that drive tumor growth and survival, by administering the right drug combination for the right person. Advances in high-throughput technologies such as microarray and next generation sequencing for gene or protein expression profiles and oncogenic signaling pathways have reinforced the discovery of treatment targets and predictive biomarkers. Because of the dramatic advances in genome-scale technologies and analytical tools, the personalized cancer therapy has been attracted oncologists' attention since the 2000s. To exploit informative biomarker is also obligatory to develop target treatment. 1 The DNA-based markers include mutations, single nucleotide polymorphisms (SNPs), chromosomal aberrations, changes in DNA copy number, differential methylation. The RNA-based biomarkers include overexpressed or underexpressed transcripts and microRNAs. The protein markers include growth factors, cell surface receptors, phosphorylation states, and peptides released by tumors into serum. In 1990s, the Human Genome Project that firstly sequenced a human genome, consumed $2,700,000,000 and was completed after 15 years, 2 however, only $1,000 whole genome sequencing is currently available. The era of personal genome sequencing has accelerated personalized target treatment (Fig. 1 ).
However, there are numerous challenges from cancer target discovery to practical clinical benefit. Though the flood of biomarkers and target agents, only a minority of patients are tested for biomarkers and treated accordingly. 
Molecular Targets and Clinical Trials in Gastric Cancer
Advances in high-throughput cancer genome sequencing, genome-wide profiling technologies, and clinical proof-of-concept, are affecting the development and approval of target agents.
Multiple key regulatory signaling pathways have been identified as key drivers of cancer through genetic and epigenetic aberrations. in 6~35% of gastric cancer, was also associated with poor clinical outcome, 18 however, the high rate of intratumoral heterogeneity of HER2 expression in gastric cancer should be considered to predict prognosis. 19 The c-MET was overexpression in 10~40% gastric cancer and activates proliferation and invasion of cancer cells after binding to HGF. 20, 21 Aberrant FGFR accelerates cancer growing and especially FGFR2 was reported to be amplified in 9% of gastric cancer. 22 The activation of PI3K/AKT/mTOR signaling pathway is correlated with poor prognostic cancer and has been studied as a treatment target. 23 Angiogenesis plays an important role in cancer development, growth, and survival, and VEGFs and receptors have been spotlighted as treatment targets. Histone deacetylase 24 and Poly (ADP-ribose) polymerase (PARP; a family of proteins involved in a number of cellular processes involving DNA repair and programmed cell death) also have been investigated as treatment targets of gastric cancer. 25 Up to date, numerous phase 2/3 trials have evaluated molecular target agents for gastric cancer (Fig. 2 ) and phase 3 trials were listed in Table 1 . 15, 16, [26] [27] [28] [29] [30] Deeper insight into molecular characteristics of gastric cancer has enabled the molecular classification of gastric cancer, the diagnosis of gastric cancer, the prediction of prognosis, the recognition of gastric cancer driver genes, and the discovery of potential therapeutic targets.
Since 2000s, the gene expression profile analysis of gastric can- cer has been performed in relatively large sample size. 11 The gene expression patterns in 90 primary gastric cancers, 14 metastatic gastric cancers, and 22 non-neoplastic gastric tissues were analyzed using cDNA microarrays representing about 30,300 genes. Gastric cancers were distinguished from non-neoplastic gastric tissues by characteristic gene expression patterns (2,565 genes; p≤0.001, false discovery rate 0.13%). The expression level IGF-2 and PLA2G2A
were significantly correlated with patient survival. There was a diversity of gene expression patterns in gastric cancer, reflecting variation in properties of tumor as it is called heterogeneity.
It was suggested that distinct gastric cancer subtypes may be distinguished by gene expression analysis. 32 Gastric cancer may be classified into 3 distinct subtypes-proximal, diffuse, and distal gastric cancer-based on histopathologic and anatomic criteria. From 36 patients with gastric cancer, 4~6 targeted biopsies of the primary tumor were obtained. Macrodissection was carried out and HG-U133A GeneChip (Affymetrix, Santa Clara, CA, USA) was used for cDNA expression analysis. Using supervised analysis, a classifier was built to distinguish the 3 gastric cancer subtypes. Gene set analysis identified several pathways that were differentially regulated in each gastric cancer subtype. These preliminary data suggested a new classification of gastric cancer for improving our understand- Negative ( However, biomarker study in breast cancer showed that 21-gene prognostic marker was approved as predictive marker for standard adjuvant chemotherapy. 34 Thus, in future study, risk score could also be applied to clinical practice of gastric cancer.
To identify the molecular underpinnings of gastric cancer, an RNA-sequencing approach (SOLiD whole-transcriptome sequencing and small RNA-sequencing; Applied Biosystems, Foster City, CA, USA) was applied to 24 gastric tumor and 6 noncancerous specimens, generating 680 million informative short reads to quantitatively characterize the entire transcriptome of gastric cancer. 
Integrative Analysis of Omics Information for Gastric Cancer
We systematically analyzed the expression profiles of mRNA, microRNA, and protein simultaneously to identify molecular biologic differences between good-and poor-prognosis patient 
Conclusions
The effect of molecular diagnostics is apparent in everywhere of cancer research. However, its application to the clinic is still limited. Although integrative molecular characterization of cancer can generate the statistical evidence for new candidate cancer targets for therapy and diagnosis, converting these into therapeutic agents and biomarkers will require deep insights to the biologic mechanism of action. New paradigm of transdisciplinary team science, which composed of innovative exploration and clinical investigation of oncologists, geneticists, pathologists, biologists, and bioinformaticians, is mandatory to realize personalized target therapy.
